| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000022593 |
| Receipt No. | R000026045 |
| Official scientific title of the study | Comfirmation of therapeutic drug monitoring for pulmonary hypertension |
| Date of disclosure of the study information | 2016/06/03 |
| Last modified on | 2016/09/21 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Comfirmation of therapeutic drug monitoring for pulmonary hypertension | |
| Title of the study (Brief title) | Comfirmation of therapeutic drug monitoring for pulmonary hypertension | |
| Region |
|
|
| Condition | ||
| Condition | pulmonary hypertension | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The aim of this study is the development of therapeutic drug monitoring (TDM) of PAH drugs (sildenafil, tadalafil, bosentan, macitentan, ambrisentan), and to perform population pharmacokinetic analysis. |
| Basic objectives2 | PK,PD |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 1. plasma drug concentration
2. laboratory tests 3. patients charactoristics 4. drug compliance |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | patients administered sildenafil, tadalafil, bosentan, ambrisentan and/or macitentan | |||
| Key exclusion criteria | patient who is decided as inadequate by doctor | |||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroshi Watanabe |
| Organization | Hamamatsu University School of Medicine |
| Division name | Department of Clinical Pharmacology and Therapeutics |
| Address | 1-20-1, Hanadayama, Higashi-ku, Hamamatsu |
| TEL | 053-435-2385 |
| hwat@hama-med.ac.jp | |
| Public contact | |
| Name of contact person | Akio Hakamata |
| Organization | Hamamatsu University School of Medicine |
| Division name | Department of Clinical Pharmacology and Therapeutics |
| Address | 1-20-1, Hanadayama, Higashi-ku, Hamamatsu |
| TEL | 053-435-2385 |
| Homepage URL | |
| hakamata@hama-med.ac.jp | |
| Sponsor | |
| Institute | Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Department of Parmacy Practice and Science, School of PharmaceuticalaScience, University of Shizuoka |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Blood samples are taken from patients who are treated with sildenafil, tadalafil, bosentan, ambrisentan, macitentan at 1-3 points per day. Administration of drugs and laboratory tests are not changed from the needs of therapy.
Plasma drug concentration, values of laboratory test, patients charactoristics and drug compliane are investigated. Pharmacokinetic analysis and evaluation of relationship between plasna concentrations and efficacy/safety are performed. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026045 |